Human TRAIL Monoclonal Antibody
Produktgrößen
1 mg
£486,00
YR0110-1MG
5 mg
£1355,00
YR0110-5MG
20 mg
£3531,00
YR0110-20MG
Über dieses Produkt
- SKU:
- YR0110
- Zusätzliche Namen:
- Apo-2L|APO2L|CD253|TANCR|TL2|TNLG6A|TRAIL
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human TRAIL
- Isotyp:
- IgG1, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0110